Maravai LifeSciences Holdings Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Reaffirmed FY24 Revenue Guidance. Also, Baird Maintained an Outperform Rating on the Stock and Raised Its Price Target...
Maravai LifeSciences Holdings Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Reaffirmed FY24 Revenue Guidance. Also, Baird Maintained an Outperform Rating on the Stock and Raised Its Price Target...
Maravai LifeSciences Holdings公佈了好於預期的第一季度財務業績並重申了24財年的收入指導，此後，該公司股價走高。此外，貝爾德維持了該股跑贏大盤的評級，並提高了目標股價...
Maravai LifeSciences Holdings Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Reaffirmed FY24 Revenue Guidance. Also, Baird Maintained an Outperform Rating on the Stock and Raised Its Price Target From $8 to $10.
Maravai LifeSciences Holdings公佈了好於預期的第一季度財務業績並重申了24財年的收入指導，此後，該公司股價走高。此外，貝爾德維持該股跑贏大盤的評級，並將其目標股價從8美元上調至10美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。